ATAD2: ATPase Family AAA Domain Containing 2
A chromatin regulator and oncogene implicated in cancer proliferation and poor prognosis
Gene Information Card
| Symbol | ATAD2 |
|---|---|
| Full Name | ATPase Family AAA Domain Containing 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 8q24.13 |
| NCBI Gene ID | 29028 ncbi.nlm.nih.gov/gene/29028 |
| Ensembl ID | ENSG00000156860 |
| UniProt ID | Q6PL18 |
| OMIM ID | 611941 |
| HGNC ID | 25823 |
| Aliases | ANCCA, PRO2000, CT137, MGC131891 |
Description
ATAD2 (ATPase Family AAA Domain Containing 2) encodes a member of the AAA+ ATPase family that functions as a chromatin regulator. The protein contains an ATPase domain and a bromodomain, enabling it to bind acetylated histones and remodel chromatin. ATAD2 acts as a coactivator for nuclear receptors such as androgen receptor and estrogen receptor, and is involved in cell proliferation, DNA replication, and transcriptional regulation. Overexpression is frequently observed in multiple cancers and correlates with poor prognosis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression enhances estrogen receptor signaling and promotes cell cycle progression | PMID: 17699751, 20406972 |
| Prostate cancer | Coactivation of androgen receptor drives proliferation and resistance to therapy | PMID: 17699751, 21502514 |
| Lung cancer | Amplification and overexpression linked to increased proliferation and metastasis | PMID: 20406972, 23104886 |
| Hepatocellular carcinoma | Upregulation promotes cell growth and correlates with poor survival | PMID: 23104886 |
| Ovarian cancer | High expression associated with aggressive disease and chemoresistance | PMID: 20406972 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 38.2 | High |
| Bone marrow | 25.1 | Medium |
| Lymph node | 22.8 | Medium |
| Spleen | 18.5 | Medium |
| Breast | 12.3 | Low |
| Lung | 10.7 | Low |
| Liver | 8.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 45.6 | Cervical cancer cell line; high expression |
| MCF7 | 52.3 | Breast cancer cell line; high expression |
| A549 | 38.9 | Lung cancer cell line; high expression |
| HepG2 | 30.2 | Hepatocellular carcinoma cell line; medium expression |
| K562 | 28.7 | Leukemia cell line; medium expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.2450A>G (p.Asn817Ser) | Missense | 0.02% (COSMIC) | Unknown; likely benign |
| c.1123C>T (p.Arg375Trp) | Missense | 0.01% (COSMIC) | Unknown; may affect ATPase activity |
| c.1789_1790insA (p.Thr597Asnfs*5) | Frameshift | 0.005% (COSMIC) | Loss of function; truncation |
| Amplification | Copy number gain | 5-10% in breast and lung cancers (COSMIC) | Gain of function; increased expression |
Mutation functional classification
Loss of Function (LOF)
Frameshift or nonsense mutations that truncate the protein, reducing ATPase or bromodomain activity.
Gain of Function (GOF)
Gene amplification or overexpression leading to enhanced chromatin remodeling and oncogenic signaling.
Dominant Negative (DN)
Not well documented; missense mutations in the ATPase domain may interfere with wild-type function.
View complete mutation data：
Gene Ontology (GO)
| • GO:0005524 - ATP binding | • GO:0016887 - ATP hydrolysis activity |
| • GO:0003682 - chromatin binding | • GO:0042393 - histone binding |
| • GO:0006338 - chromatin remodeling | • GO:0005634 - nucleus |
| • GO:0008283 - cell proliferation | • GO:0006357 - regulation of transcription by RNA polymerase II |
Pathways
• Estrogen receptor signaling pathway
• Androgen receptor signaling pathway
• Cell cycle (G1/S transition)
• Chromatin remodeling
Protein Summary
ATAD2 is a 1390-amino acid nuclear protein with an N-terminal AAA+ ATPase domain and a C-terminal bromodomain. It functions as a chromatin remodeler that binds acetylated histones, facilitating transcription of genes involved in cell cycle progression and proliferation. ATAD2 acts as a coactivator for nuclear receptors (e.g., androgen receptor, estrogen receptor) and is frequently overexpressed in cancers, where it promotes tumor growth and correlates with poor prognosis. The protein is considered a potential therapeutic target.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ATAD2 Knockout HEK293 Cell Line | EDJ-KQ8965 | Human | 29028 | Details Get a Quote |
| ATAD2B Knockout HEK293 Cell Line | EDJ-KQ11419 | Human | 54454 | Details Get a Quote |
| GATAD2A Knockout HEK293 Cell Line | EDJ-KQ13569 | Human | 54815 | Details Get a Quote |
| GATAD2B Knockout HEK293 Cell Line | EDJ-KQ13570 | Human | 57459 | Details Get a Quote |
| GATAD2B Knockout HCT 116 Cell Line | EDJ-KQ41960 | Human | 57459 | Details Get a Quote |
| GATAD2A Knockout A-549 Cell Line | EDJ-KQ43214 | Human | 54815 | Details Get a Quote |
| GATAD2A Knockout HCT 116 Cell Line | EDJ-KQ43215 | Human | 54815 | Details Get a Quote |
| GATAD2A Knockout HeLa Cell Line | EDJ-KQ43216 | Human | 54815 | Details Get a Quote |
| ATAD2 Knockout A-549 Cell Line | EDJ-KQ35359 | Human | 29028 | Details Get a Quote |
| ATAD2 Knockout HCT 116 Cell Line | EDJ-KQ35360 | Human | 29028 | Details Get a Quote |
| ATAD2 Knockout HeLa Cell Line | EDJ-KQ35361 | Human | 29028 | Details Get a Quote |
| ATAD2B Knockout HeLa Cell Line | EDJ-KQ38329 | Human | 54454 | Details Get a Quote |
| ATAD2B Knockout A-549 Cell Line | EDJ-KQ39657 | Human | 54454 | Details Get a Quote |
| ATAD2B Knockout HCT 116 Cell Line | EDJ-KQ39658 | Human | 54454 | Details Get a Quote |
| GATAD2B Knockout A-549 Cell Line | EDJ-KQ43217 | Human | 57459 | Details Get a Quote |
Displaying Records 1 To 15 Of 17 Records
